KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial. PMID 39808795 · Blood Adv · 2025-Apr-22 The report is a secondary/biomarker analysis within a Phase III trial. While it includes time-to-event data and HRs, the primary focus is on the prognostic impact of clonal hematopoiesis, not the reporting of the trial's primary or key secondary efficacy results for the drug intervention. Therefore, it does not meet the inclusion criteria for original formal-result reports of the randomized trial's efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies. PMID 39774762 · Blood Adv · 2025-Apr-22 The record describes a Phase III randomized trial of a drug (iptacopan) for paroxysmal nocturnal hemoglobinuria (an oncologic/hematologic malignancy). However, the abstract exclusively reports on patient-reported outcomes of fatigue and quality of life (using FACIT-Fatigue and EORTC QLQ-C30 questionnaires). It does not mention or provide any data on a time-to-event efficacy endpoint such as overall survival, progression-free survival, disease-free survival, or a time-to-event analysis via Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the required criterion for a primary or key secondary time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial. PMID 39808757 · J Clin Oncol · 2025-Apr-20 The study is a randomized, oncology trial in humans comparing two diagnostic/staging pathways (mpMRI vs. TURBT) for bladder cancer. It reports a time-to-event endpoint (Time to Correct Treatment). However, it is excluded because the intervention is non-drug (diagnostic/procedural), not a drug-containing therapy. The time-to-event endpoint is not a standard efficacy endpoint like OS or PFS but a process-of-care measure. No drug intervention is present.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results. PMID 39668137 · J Clin Oncol · 2025-Apr-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. PMID 40284030 · Pharmaceuticals (Basel) · 2025-Apr-19 This is a real-world, non-randomized study (AENEID) evaluating IsaKd. While it reports time-to-event efficacy results (PFS, OS) for a drug regimen, it is not a randomized controlled trial and does not represent the original Phase III/IIIb trial results for the drug combination. The original Phase III trial (IKEMA) is referenced but is not the subject of this record.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A randomized, blinded controlled phase 3 trial in healthy participants aged 10-60 years old. PMID 40188565 · Vaccine · 2025-Apr-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial. PMID 40158526 · Lancet · 2025-Apr-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial. PMID 40158524 · Lancet · 2025-Apr-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine. PMID 40081152 · Vaccine · 2025-Apr-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial. PMID 40251644 · J Transl Med · 2025-Apr-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients. PMID 40250846 · BMJ Open Respir Res · 2025-Apr-17 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of treating Helicobacter pylori infection on seizure frequency in children with drug-resistant idiopathic generalized epilepsy: a randomized controlled trial. PMID 40247384 · Ital J Pediatr · 2025-Apr-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A study protocol for the CHinA National CancEr screening (CHANCES) trial: a randomized controlled study to compare the screening strategies for lung cancer and colorectal cancer. PMID 40247218 · BMC Cancer · 2025-Apr-17 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of inclisiran based on background lipid-lowering treatment. PMID 40242982 · Eur J Prev Cardiol · 2025-Apr-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. PMID 39927615 · N Engl J Med · 2025-Apr-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Short-term outcomes of KangDuo surgical robot- versus Da Vinci surgical robot-assisted radical resection of colorectal cancer: a prospective cohort study. PMID 40241095 · BMC Surg · 2025-Apr-16 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Physical rehabilitation program for cardiorespiratory health and quality of life among breast cancer survivors in UAE: a randomized control trial. PMID 40241061 · BMC Cancer · 2025-Apr-16 The study is an oncology randomized controlled trial with original results, but it is a physical rehabilitation program (non-drug only) and the primary endpoints are cardiorespiratory fitness and quality of life, not a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of lenalidomide consolidation on health-related quality of life in chronic lymphocytic leukemia: ancillary study of the phase III CLL6-RESIDUUM trial. PMID 40240989 · BMC Cancer · 2025-Apr-16 This is an ancillary quality-of-life analysis of a Phase III RCT in chronic lymphocytic leukemia. While the parent trial is eligible for inclusion, this specific report focuses solely on HRQoL outcomes, which are excluded per the adjudication rules (non-efficacy endpoint). No time-to-event efficacy endpoint is reported or signaled in this abstract.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Interventions to Reduce Serum Per- and Poly-Fluoroalkyl Substances Levels, Improve Cardiovascular Risk Profiles, and Improve Epigenetic Age Acceleration in US Firefighters: Protocol for Randomized Controlled Trial. PMID 40239196 · JMIR Res Protoc · 2025-Apr-16 The study is not an oncology trial; it is an occupational health intervention trial in firefighters focused on reducing PFAS levels and cardiovascular risk. It is a protocol for a randomized trial, not an original result report. The interventions (blood/plasma donation, physical activity, fasting) are non-pharmacologic. No time-to-event efficacy endpoint (OS, PFS, etc.) is described. The publication type is 'Clinical Trial Protocol'.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Vaccines for preventing infections in adults with solid tumours. PMID 40237463 · Cochrane Database Syst Rev · 2025-Apr-16 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of early multidisciplinary team interventions on dietary management behavior in breast cancer patients: a pilot randomized controlled trial. PMID 40234862 · BMC Cancer · 2025-Apr-15 The study is a randomized oncology trial with a drug-containing intervention (chemotherapy), but it is not a Phase III/IIIb or Phase II/III trial, and its primary endpoints are not time-to-event efficacy measures.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparative efficacy and safety in low-intensity treatment for acute myeloid leukemia in older patients: a systematic review and network meta-analysis. PMID 40229815 · Eur J Med Res · 2025-Apr-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The effect of doxepin 3 mg on sleep latency: a pooled analysis of two phase 3 trials. PMID 40229607 · Sleep Breath · 2025-Apr-14 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Design of a randomised, placebo-controlled, double-blind multicentre study assessing the effect of colchicine on the incidence of knee or hip replacements in symptomatic knee or hip osteoarthritis: the ECHO trial. PMID 40228852 · BMJ Open · 2025-Apr-14 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial. PMID 40222976 · Signal Transduct Target Ther · 2025-Apr-14 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies. PMID 40086437 · Cancer Cell · 2025-Apr-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy. PMID 40220155 · J Neurol · 2025-Apr-12 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial. PMID 40158525 · Lancet · 2025-Apr-12 The trial is an oncology screening study comparing non-drug interventions (colonoscopy vs. faecal immunochemical test). The primary endpoint is colorectal cancer mortality at 10 years, which is a binary outcome (risk difference/RR), not a time-to-event endpoint with survival analysis (Kaplan-Meier or HR). No drug intervention is present. Therefore, it does not meet the criteria for a drug-containing intervention with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Tadalafil on cardiac function and left ventricular dimensions in Duchenne muscular dystrophy: safety and cardiac MRI substudy results from a randomized, placebo-controlled trial. PMID 40217158 · BMC Cardiovasc Disord · 2025-Apr-11 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Corrigendum to "Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study" [Vaccine (38) (2020) 5194-5201]. PMID 39999539 · Vaccine · 2025-Apr-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME study. PMID 40211191 · BMC Cancer · 2025-Apr-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. PMID 40162636 · N Engl J Med · 2025-Apr-10 The trial is a Phase III randomized study with a drug intervention and time-to-event endpoint. However, the endpoints are management of cancer-associated venous thromboembolism (a complication) and bleeding (safety), not a primary or key secondary oncologic efficacy endpoint (like OS, PFS, DFS). Therefore, it does not meet the criteria for an oncology efficacy trial for KM digitization.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion. PMID 39908448 · N Engl J Med · 2025-Apr-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial. PMID 39761503 · J Clin Oncol · 2025-Apr-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study. PMID 39656830 · Inflamm Bowel Dis · 2025-Apr-10 The study is a randomized Phase 2b/3 trial with a drug intervention (filgotinib) and is an original research report. However, it is not an oncology study; it investigates ulcerative colitis. Furthermore, the primary endpoints are biomarker changes and clinical scores, not time-to-event endpoints like OS, PFS, etc. Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS. PMID 39652826 · Blood · 2025-Apr-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial. PMID 39652594 · J Clin Oncol · 2025-Apr-10 The record describes a randomized trial with a time-to-event endpoint (PFS) and a drug intervention, which meets most criteria. However, the phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, publication types, or deterministic review). The deterministic review flagged 'phase3_evidence_unclear' due to lack of explicit Phase III evidence in PubMed metadata. Since the phase cannot be established from the provided information, the trial is ineligible for the Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis. PMID 39018016 · Inflamm Bowel Dis · 2025-Apr-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Similar Efficacy of Mesalazine in Adult and Older Adult Ulcerative Colitis Patients: Post Hoc Analysis of a Randomized Noninferiority Trial of 1600 mg vs 400 mg Tablets. PMID 38902993 · Inflamm Bowel Dis · 2025-Apr-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program. PMID 38899786 · Inflamm Bowel Dis · 2025-Apr-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Trusted health system implementation strategies to increase vaccination (TRUE SYNERGI): a stepped-wedge cluster randomized trial to reduce HPV-related cancers. PMID 40205591 · BMC Public Health · 2025-Apr-09 This is a protocol for an implementation science study (stepped-wedge cluster randomized trial) testing strategies to increase HPV vaccination rates in primary care settings. While oncology-related (prevention of HPV-related cancers), it does not meet the core eligibility criteria: it is not a drug-containing intervention (vaccine is preventive, not therapeutic), it is a protocol without results, and the primary endpoint is not a time-to-event efficacy outcome (e.g., OS, PFS, DFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
"There's a lot of unknowns": a thematic analysis of the experiences of young adults with cancer who died during a psychosocial intervention trial. PMID 40205419 · BMC Palliat Care · 2025-Apr-09 The record describes a qualitative thematic analysis of patient experiences from a psychosocial intervention RCT. While it is an oncology RCT involving humans, it fails eligibility because: 1) The intervention is psychosocial, not drug-containing. 2) There is no time-to-event efficacy endpoint (e.g., OS, PFS, KM, HR). 3) The report type is a secondary/subgroup qualitative analysis, not the primary or definitive result of a Phase III drug trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Epidemiological Analysis of Obesity-related co-morbidities and mortality among post- menopausal women diagnosed with endometrial cancer: A Randomized Controlled Trial. PMID 40297687 · Res Sq · 2025-Apr-08 Study is an epidemiological analysis of comorbidities and mortality in endometrial cancer patients from the WHI, but does not involve a drug intervention as a key component. While it uses time-to-event methodology (Cox regression), it fails the core requirement of having a drug-containing intervention. The randomized trial nature refers to the WHI trial structure, but the analysis is observational within that context. Phase information is not explicitly provided.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
SMALL: open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer-protocol for a phase III randomised multicentre trial. PMID 40204306 · BMJ Open · 2025-Apr-08 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Topical tacrolimus for the amelioration of breast cancer-related lymphedema (TACLE Trial): a study protocol for a randomized, double-blind, placebo-controlled phase II/III trial. PMID 40200322 · Trials · 2025-Apr-08 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial. PMID 40200187 · BMC Cancer · 2025-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial. PMID 40199888 · Nat Commun · 2025-Apr-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial. PMID 40199609 · J Immunother Cancer · 2025-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effectiveness of Stromal Vascular Fraction (SVF) and Platelet-Rich Plasma (PRP) in Patients With Knee Osteoarthritis: Protocol for a Phase 3, Prospective, Randomized, Controlled, Multicenter Study (SPOST Study). PMID 40198111 · JMIR Res Protoc · 2025-Apr-08 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update. PMID 39883948 · Blood Adv · 2025-Apr-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -